<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04735263</url>
  </required_header>
  <id_info>
    <org_study_id>2020P001265</org_study_id>
    <nct_id>NCT04735263</nct_id>
  </id_info>
  <brief_title>Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD</brief_title>
  <acronym>DELPHI</acronym>
  <official_title>Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      interventional trial for off label use of high dose atorvastatin 80 mg in intermediate AMD&#xD;
      patients and correlate recovery response measured by dark adaptation recovery time with&#xD;
      drusen volume reduction measured by SD-OCT&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dark adaptation recovery time is a sensitive marker of AMD progression in intermediate AMD,&#xD;
      largely owing to drusen volume providing a transport barrier that slows the transfer of&#xD;
      nutrients between the choroid and photoreceptors2. Consequently, dark adaptation may provide&#xD;
      an early indication of response vs. nonresponse, aiding case-by-case decisions on&#xD;
      continuation of treatment when patients experience adverse side effects (e.g., elevated CPK&#xD;
      or liver enzymes) or when atorvastatin provides insufficient lipid control in patients also&#xD;
      at high-risk for cardiovascular disease (and switching to an alternative statin might be&#xD;
      desirable).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective interventional trial for off label use of FDA approved drug</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Dark Adaptation recovery time measured by change in Rod Intercept time (RIT)</measure>
    <time_frame>18 Months</time_frame>
    <description>Determine weather improvement in dark adaptation recovery time or rod intercept time (RIT) can be used as an early indicator of positive response to high dose statin therapy for intermediate AMD patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in drusen volume measured by Spectral Domain OCT</measure>
    <time_frame>18 months</time_frame>
    <description>To measure and quantify improvement or positive response to high dose statin therapy in patients with intermediate AMD using drusen volume measured by SDOCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To correlate visual functions of dark adaption with change in drusen volume</measure>
    <time_frame>18 months</time_frame>
    <description>Patient will have Dark Adaptation testing performed to check change in vision function with changes in drusen volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To correlate Best Corrected Visual Acuity and retinal structural evaluation of study patients</measure>
    <time_frame>18 months</time_frame>
    <description>Patient will have Best Corrected visual acuity, testing performed to check changes in vision function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate change in contrast sensitivity and retinal structural evaluation of study patients</measure>
    <time_frame>18 months</time_frame>
    <description>Patient will have quantitative contrast sensitivity function testing performed to check change in vision function with changes in drusen volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate change in microperimetry visual functional and retinal structural evaluation of study patients</measure>
    <time_frame>18 months</time_frame>
    <description>Patient will have microperimetry function testing performed to check change in this vision function with changes in drusen volume</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Intermediate Age-Related macular degeneration patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects can have either:&#xD;
Bilateral high-risk iAMD&#xD;
High-risk iAMD in one eye with GA and/or CNV in the fellow eye No control arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 80mg</intervention_name>
    <description>Patient will be receiving 80mg of Atorvastatin, if they are able to tolerate it from the start to the end of the study.</description>
    <arm_group_label>Intermediate Age-Related macular degeneration patients</arm_group_label>
    <other_name>Lipitor 80 mg(Brand name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects with intermediate AMD diagnosis in one or both eyes will be considered,&#xD;
             regardless the severity stage and subtype of disease in the other eye.&#xD;
&#xD;
        High-risk iAMD (numerous large, confluent drusen covering â‰¥ 0.5 disk area, with or without&#xD;
        pigmentary changes but having no evidence of GA or CNV) in the study eye&#xD;
&#xD;
        Subjects can have either:&#xD;
&#xD;
        (i) Bilateral high-risk iAMD, or (ii) High-risk iAMD in one eye with GA and/or CNV in the&#xD;
        fellow eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient previously taking high dose Atorvastatin 80 mg&#xD;
&#xD;
          -  Patients previously taking other statins than high dose atorvastatin, in whom primary&#xD;
             care provider (PCP) feels cannot be safely moved to high dose atorvastatin or those in&#xD;
             which high dose atorvastatin is deemed contraindicated by PCP&#xD;
&#xD;
          -  Patients with known adverse reaction to statins&#xD;
&#xD;
          -  Patients with severe renal disease or multiple comorbidities&#xD;
&#xD;
          -  Age &gt;85 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with concomitant use of cyclosporine&#xD;
&#xD;
          -  Active uveitis;&#xD;
&#xD;
          -  Ocular infection;&#xD;
&#xD;
          -  Any retinopathy other than AMD;&#xD;
&#xD;
          -  Media opacities;&#xD;
&#xD;
          -  Refractive error equal or superior to 6 diopters (spherical equivalent);&#xD;
&#xD;
          -  Any previous retina surgery;&#xD;
&#xD;
          -  Other ocular surgery or intra-ocular procedure in the study eye (injection other than&#xD;
             anti angiogenic injection, laser) within the 90 days prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John B Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary, Harvard Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John B Miller, MD</last_name>
    <phone>617-573-3750</phone>
    <email>John_miller@meei.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deeba Husain</last_name>
    <phone>617-573-3750</phone>
    <email>Deeba_Husain@meei.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John B Miller, MD</last_name>
      <phone>617-573-3750</phone>
      <email>John_Miller@meei.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vavvas DG, Daniels AB, Kapsala ZG, Goldfarb JW, Ganotakis E, Loewenstein JI, Young LH, Gragoudas ES, Eliott D, Kim IK, Tsilimbaris MK, Miller JW. Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. EBioMedicine. 2016 Feb 4;5:198-203. doi: 10.1016/j.ebiom.2016.01.033. eCollection 2016 Mar.</citation>
    <PMID>27077128</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>John B. Miller, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

